New European trial initiated to identify response to talimogene laherparepvec using intratumoural CD8+ T lymphocytes as biomarker
Amgen announced the initiation of a clinical trial, NCT02366195, to determine whether baseline CD8+ T lymphocytes density is a biomarker of response to talimogene laherparepvec, an investigational oncolytic immunotherapy, in patients with unresected stages IIIB to IV melanoma. The first subject has enrolled into the study, with the goal of including approximately 110 patients across 49 clinical trial sites in 11 different countries in Europe.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Oncology intratumoural CD8 T lymphocytes Latest News melanoma stage IIIB Source Type: news
More News: Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Melanoma | Skin Cancer | Study